

Session Title: #17: Bone Therapy in Breast Cancer: Why, When, and What's Next?

Session Type: Education Session

Date: Friday, June 4

Location: E Hall D1

Time: 1:00 PM - 2:15 PM

- The bone microenvironment and the potential antitumor effects of bone therapy.

Theresa Guise, MD

- Systemic therapy for bone metastasis: Past, Present, and Future

Gabriel N. Hortobagyi, MD, FACP

- Is there a role for bisphosphonates in the adjuvant setting?

Catherine H. Van Poznak, MD

Session Title: #23: Clinical Practice: The Challenge of Financial Survival

Session Type: Education Session

Date: Friday, June 4

Location: E353

Time: 1:00 PM - 2:15 PM

- The Changing Face of Oncology Practice

Elaine L. Towle, CMPE

- Creating a Product for the Future

William M. Jordan, DO

- The Hospital Refuge: Oasis or Mirage.

Jeffery C. Ward, MD

Session Title: #78: Neurologic Complications of Cancer Therapies

Session Type: Education Session

Date: Friday, June 4

Location: S100b

Time: 1:00 PM - 2:15 PM

- Peripheral Neuropathies
David Schiff, MD
 - CNS complications (including effects of targeted therapies)
Patrick Y. Wen, MD
 - Radiation and chemotherapy effects on cognition (including chemo brain)
Michelle Monje, MD, PhD
-

Session Title: #110: Use of Induction Chemotherapy in Clinical Practice

Session Type: Education Session

Date: Friday, June 4

Location: S406 (Vista Room)

Time: 1:00 PM - 2:15 PM

- Combined Modality Therapy in Perspective
Everett E. Vokes, MD
- Induction Chemotherapy and Sequential Therapy for Locally Advanced Squamous Cell Cancer of the Head and Neck in Clinical Practice

Marshall R. Posner, MD

- Radiation oncology perspective. Dr. Beitler is at Emory University Winship Cancer Institute in Atlanta GA.

Jonathan Jay Beitler, MD, MBA, FACR

Session Title: #232: Fundamentals of Clinical Trial Design and Methodology

Session Type: Extended Education Session

Date: Friday, June 4

Location: S100a

Time: 1:00 PM - 3:15 PM

- Overview and Introduction of Speakers
Michael Paul Link, MD
- Clinical Trials Issues and Design
James L. Abbruzzese, MD
- Statistical Principles in Clinical Trials
Susan G. Hilsenbeck, PhD

- Ethics in Cancer Clinical Trials
Steven Joffe, MD, MPH
 - Practical Considerations in Clinical Trial Design
Ian Tannock, MD, PhD
-

Session Title: #233: Grant Writing Workshop I: Basic Grant Writing

Session Type: Extended Education Session

Date: Friday, June 4

Location: S106a

Time: 1:00 PM - 3:30 PM

- NCI Training and Career Development Grants
Jonathan S. Wiest, PhD
 - The ASCO Cancer Foundation Grants Program
Jennifer C. King, PhD
 - Choosing a Mentor and Obtaining Letters of Support
Merrill J. Egorin, MD
 - Developing Hypothesis and Stating Aims
Charles M. Rudin, MD, PhD
 - Statistical Considerations
Donna S. Neuberg, ScD
 - R21 Grants, Perseverance, and Resubmission
William G. Blum, MD
 - Grant Writing Pearls
Mary L. (Nora) Disis, MD
-

Session Title: #235: Sex and the Survivor

Session Type: Extended Education Session

Date: Friday, June 4

Location: E Arie Crown Theater

Time: 1:00 PM - 3:15 PM

- Overview of Current Strategies to Prevent and Treat Cancer-Related Sexual Dysfunction
Leslie R. Schover, PhD

- Preventing and Treating Sexual Dysfunction in Women with Breast Cancer

Patricia A. Ganz, MD

- Gynecologic Approach to Women's Cancer-Related Sexual Dysfunction

Stacy Tessler Lindau, MD, MAPP

- Urologic Treatment of Men's Cancer-Related Sexual Dysfunction

John Mulhall, MD

- Sexuality in survivors of colorectal cancer

Francesco Di Fabio, MD

- SPIRIT: Peer Counseling to Promote Reproductive Health in African-American Breast Cancer Survivors

Michelle Marion Rhodes, PhD

- Sexual Impact of Being at High Genetic Risk for Cancer

Sharon L. Bober, PhD

Session Title: #236: Advances in Prevention of Major Malignancies

Session Type: Extended Education Session

Date: Friday, June 4

Location: E354b

Time: 1:00 PM - 3:15 PM

- Advances in Prevention of Major Malignancies

Victor G. Vogel, MD

- 5-alpha reductase inhibitors for prostate cancer prevention

Ian Thompson, MD

- Chemoprevention of colorectal cancer

Monica M. Bertagnoli, MD

- SERMs in the Prevention of Breast Cancer

Jack Cuzick, PhD

Session Title: #237: Cancer and Thrombosis: Risk, Prevention, and Treatment

Session Type: Extended Education Session

Date: Friday, June 4

Location: E354a

Time: 1:00 PM - 3:15 PM

- Review currently available guidelines for the prevention of cancer-associated thrombosis

Gary H. Lyman, MD, MPH

- Review the incidence and prevalence of cancer-associated thrombosis

Alok A. Khorana, MD

- Risk of VTE in patients receiving newer cancer therapies

Howard A. Liebman, MD

- Prevention of VTE in hospitalized medical patients

Charles W. Francis, MD

- Prevention of VTE in surgical cancer patients

Ajay Kumar Kakkar, MD

- Prevention of VTE in ambulatory cancer patients receiving chemotherapy

Mark Norman Levine, MD

- Current and future clinical trials of VTE prophylaxis in cancer patients

Anna Falanga, MD

- Diagnosis and initial treatment of VTE in cancer patients

Craig M. Kessler, MD

- Special populations and extended anticoagulation of cancer patients for the prevention of recurrent VTE prevention of recurrent VTE

Agnes Y. Y. Lee, MD, MSc, FRCP(C)

Session Title: #260: Maintenance of Certification and Lifelong Learning Workshop

Session Type: Extended Education Session

Date: Friday, June 4

Location: E451a

Time: 1:00 PM - 4:00 PM

- MOC Module Presenter

Hyman Bernard Muss, MD

- MOC Module Presenter

Matthew I. Milowsky, MD

- MOC Module Presenter

Philip Jay Bierman, MD

Session Title: #275: Childhood Cancer Survivorship: Lessons Learned and Future Steps

Session Type: Extended Education Session

Date: Friday, June 4

Location: S504

Time: 1:00 PM - 3:15 PM

- Childhood Cancer Survivorship: Lessons Learned and Future Steps

Kevin C. Oeffinger, MD

- Current guidelines for follow up of the survivors of pediatric cancers. Current new areas of research including issues related to genetic susceptibility to toxicities

Smita Bhatia, MD, MPH

- Long-term psycho-social effects following the treatment of pediatric cancers.

Christopher Recklitis, MPH, PhD

- Discussion of the Childhood Cancer Survivor Study (CCSS)

Gregory T. Armstrong, MD, MSCE

- Discussion of the Childhood Cancer Survivor Study (CCSS)

Leslie L. Robison, PhD

Session Title: #277: On the Shoulders of Giants: Historical Perspective on Drug Development and Renal Cancer

Session Type: Extended Education Session

Date: Friday, June 4

Location: E350

Time: 1:00 PM - 3:30 PM

- Moderator

Lisa A. Carey, MD

- Drug Development

Manuel Hidalgo, MD, PhD

- Renal Cancer

Robert John Motzer, MD

- Breakout Session - Renal Cell Biologist

William Kaelin, MD

- Breakout Session - Case Study Presenter

Session Title: #178: Gastrointestinal (Noncolorectal) Cancer

Session Type: Poster Discussion Session

Date: Friday, June 4

Location: E450b

Time: 2:00 PM - 6:00 PM

- Gastrointestinal (Noncolorectal) Cancer

Andrea Wang-Gillam, MD, PhD

- Gastrointestinal (Noncolorectal) Cancer

Gauri R. Varadhachary, MD

1 #4013-5-fluorouracil, leucovorin, and oxaliplatin with or without docetaxel in elderly (65 years or older) patients with esophagogastric cancer: FLOT65+ trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

Salah-Eddin Al-Batran

2 #4014-Random assignment multicenter phase II study of modified docetaxel, cisplatin, fluorouracil (mDCF) versus DCF with growth factor support (GCSF) in metastatic gastroesophageal adenocarcinoma (GE).

Manish Shah

3 #4015-Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402): Final report.

Tomono Kishimoto, MD

5 #4017-Validation of tumoral matrix-metalloproteinase-9 (MMP-9) mRNA expression as a molecular prognostic factor for metastatic gastroesophageal cancer.

Akin Atmaca

- Discussion

Peter C. Enzinger, MD

6 #4018-Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach (ITACA-S) trial: Comparison of a sequential treatment with irinotecan (CPT-11) plus 5-fluorouracil (5FU)/folinic acid (LV) followed by docetaxel and cisplatin versus a 5-FU/LV regimen as postoperative treatment for radically resected gastric cancer: Tolerability and feasibility of a phase III study.

Emilio Bajetta, MD

7 #4019-Preliminary safety data from a randomized trial of perioperative epirubicin, cisplatin plus capecitabine (ECX) with or without bevacizumab (B) in patients (pts) with gastric or oesophagogastric junction (OGJ) adenocarcinoma.

Maria Franca Clara Okines

8 #4020-Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma (JCOG0110): Analyzes of operative morbidity, operation time, and blood loss.

Takeshi Sano

9 #4021-Perioperative chemotherapy with oxaliplatin/5-fluorouracil/leucovorin (FOLFOX7) for locally advanced gastric cancer: Final results of a prospective multicenter phase II study (BJSA-01) with 2 years follow-up.

Jiafu Ji

10 #4022-Meta-analysis of preoperative chemotherapy (CTX) versus primary surgery for locoregionally advanced adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus (GE adenocarcinoma).

Ulrich Ronellenfitsch, MD

11 #4023-Comparison of the 2010 AJCC TNM staging system with a modified lymph node ratio staging system in 7,233 gastric cancer patients.

Jiping Wang

- Discussion

Stephen Swisher, MD

12 #4024-Effect of peretinoin on recurrence of hepatocellular carcinoma (HCC): Results of a phase II/III randomized placebo-controlled trial.

Kiwamu Okita

13 #4025-A randomized phase II/III trial of three weekly cisplatin based transarterial chemoembolization (TACE) versus embolization (TAE) alone for hepatocellular cancer (HCC).

Tim Meyer

14 #4026-Study in Asia of the combination of transcatheter arterial chemoembolization (TACE) with sorafenib in patients with hepatocellular carcinoma (HCC) trial (START): Second interim safety and efficacy analysis.

Young Hwa Chung

15 #4027-European multicenter evaluation of survival for patients with hepatocellular carcinoma (HCC) treated by radioembolization with 90y-labeled resin microspheres.

Bruno Sangro

16 #4028-The impact of antiviral therapy on the outcome of hepatitis B viral (HBV)-related hepatocellular carcinoma (HCC) detected in surveillance program.

Vincent W.S. Wong

17 #4029-Randomized phase II trial of s-1 and cisplatin versus gemcitabine and cisplatin in advanced biliary tract adenocarcinoma.

Myoung Joo Kang

18 #4030-A randomized phase II study of TSU-68 in patients (pts) with hepatocellular carcinoma (HCC) treated by transarterial chemoembolization (TACE).

Yasuaki Arai

- Discussion

Jennifer J. Knox, MD, FRCP

19 #4031-Cox proportional hazard analysis of sunitinib (SU) efficacy across subgroups of patients (pts) with progressive pancreatic neuroendocrine tumors (NET).

Eric Raymond

20 #4032-The role of octreotide imaging in detecting neuroendocrine tumors (NETs) in 2010: Do we still need it?

Leonard Saltz

21 #4033-A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: Final results of the CONKO-004 trial.

Hanno Riess

22 #4034-ECOG 2204: An intergroup randomized phase II study of cetuximab (Ce) or bevacizumab (B) in combination with gemcitabine (G) and in combination with capecitabine (Ca) and radiation (XRT) as adjuvant therapy (Adj Tx) for patients (pts) with completely-resected pancreatic adenocarcinoma (PC).

Jordan Berlin

23 #4035-A placebo-controlled, randomized phase II study of conatumumab (C) or AMG 479 (A) or placebo (P) plus gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (mPC).

Hedy Lee Kindler

24 #4036-The combination of a chemotherapy doublet (gemcitabine plus capecitabine) with a biologic doublet (bevacizumab plus erlotinib) in patients with advanced pancreatic adenocarcinoma: The TARGET study.

David J. Watkins

25 #4037-A multicenter randomized controlled trial of gemcitabine (G) alone versus gemcitabine and s-1 combination therapy (GS) in patients with unresectable advanced pancreatic cancer (PC): GEMSAP study.

Yousuke Nakai

- Discussion

Milind M. Javle, MD

Session Title: #182: Head and Neck Cancer

Session Type: Poster Discussion Session

Date: Friday, June 4

Location: S403

Time: 2:00 PM - 6:00 PM

- Head and Neck Cancer

Ranee Mehra, MD

- Head and Neck Cancer

Cherie-Ann Nathan, MD

1 #5512-Long-term results from TAX324: A phase III trial of sequential therapy comparing TPF to PF in locally advanced (LA) squamous cell cancer of the head and neck (HNC).

Jochen H. Lorch

2 #5513-Phase II induction cetuximab (C225), paclitaxel (P), and carboplatin (C) followed by chemoradiation with C225, P, C, and RT 68-72Gy for stage III/IV head and neck squamous cancer: Primary site organ preservation and disease control at 2 years (ECOG, E2303).

Harold J. Wanebo

3 #5514-TPF induction-radioimmunochemotherapy for the treatment of advanced head and neck cancer.

Wolf-Oliver Jordan

4 #5515-Induction docetaxel, cisplatin, and cetuximab (TPE) followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locoregionally advanced head and neck cancer (HNC): Mature results with HPV analysis.

Robert L. Ferris

5 #5516-Radiation alone (RT) versus RT with concomitant chemotherapy (CT) in stages III and IV oropharynx carcinoma: Ten-year results of the 94-01 GORTEC randomized study.

Gilles Calais

6 #5517-Need for postradiotherapy neck dissection by tumor site and nodal stage for head and neck cancer.

Juliette Thariat

7 #5518-Clinical efficacy and tolerability of continuous course reirradiation with concurrent weekly carboplatin-paclitaxel for locally recurrent, nonmetastatic squamous cell carcinoma of the head and neck (SCCHN).

Anjali Marwaha

- Discussion

Danny Rischin, MD

9 #5520-Use of XPF expression in tumors and XPF single nucleotide polymorphisms to predict clinical outcome in head and neck cancer.

Alec E. Vaezi, MD, PhD

10 #5521-Gene expression profiling of oral preneoplastic lesions (OPL) from a prospective prevention trial.

Pierre Saintigny

11 #5522-Comparison of primary site biopsies and transverse surgical sections of squamous cell carcinoma of the head and neck for translational research analysis.

Markus Hambek

12 #5523-Association of circulating tumor cells with lymph node metastasis in squamous cell carcinoma of the head and neck region (SCCHN).

Inge Tinhofer

13 #5524-Usefulness of interim FDG-PET after induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck receiving induction chemotherapy and definitive chemoradiotherapy.

Sung-Bae Kim

- Discussion

Cherie-Ann Nathan, MD

14 #5525-Oropharynx cancer (OPC) in TAX 324: Human papillomavirus (HPV) and survival.

Marshall R. Posner, MD

15 #5526-A population-based evaluation of incidence trends in oropharynx cancer (OP) focusing on socioeconomic status (SES), sex, and race/ethnicity.

A. Dimitrios Colevas, MD

16 #5527-Human papillomavirus (HPV) transmission from oropharyngeal cancer patients to sexual partners.

Vassiliki Papadimitrakopoulou

17 #5528-Relationship between epidermal growth factor receptor (EGFR) gene copy number, p16 status, and outcome in locally advanced squamous cell carcinoma of the head and neck (LASCCHN).

Benjamin J. Solomon

18 #5529-Plasma human papillomavirus (HPV) DNA as a potential tool for tumor detection and monitoring response in HPV-related oropharyngeal carcinoma (OP).

Hongbin Cao

- Discussion

Anil Chaturvedi, DVM, PhD

19 #5530-An open-label, randomized, study of h-R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): Four-year survival results from a phase IIb study.

K. Govind Babu

20 #5531-Phase II trial of the irreversible oral pan-HER inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).

Christophe Le Tourneau, MD, PhD

21 #5532-A phase II study of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic or recurrent squamous cell cancer of the head and neck (SCCHN).

Anita Lynn Sabichi, MD

22 #5533-Pemetrexed (P) and bevacizumab (B) in patients (pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Final results and correlation with TS, MTHFR, and VEGF gene polymorphisms.

Athanassios Argiris

23 #5534-Is there a role for adjuvant cetuximab after radiotherapy (RT) plus cetuximab in patients (pts) with locally advanced squamous cell carcinoma of the oropharynx? A phase II randomized trial.

Ricard Mesia

24 #5535-Chemoprevention with erlotinib and celecoxib in advanced premalignant lesions of the head and neck: Results of a phase I study.

Nabil F. Saba

25 #5536-Phase II study and tissue correlative studies of AZD6244 (ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma (IRPTC) and papillary thyroid carcinoma (PTC) with follicular elements.

Amy S. Lucas

- Discussion

Ranee Mehra, MD

Session Title: #187: Lymphoma and Plasma Cell Disorders

Session Type: Poster Discussion Session

Date: Friday, June 4

Location: E450a

Time: 2:00 PM - 6:00 PM

- Lymphoma and Plasma Cell Disorders

Nancy Bartlett, MD

- Lymphoma and Plasma Cell Disorders

Robert Z. Orlowski, MD, PhD

1 #8022-Modified high-dose melphalan and autologous stem cell transplantation (mHDM/SCT) in the treatment of AL amyloidosis (AL) and/or high-risk myeloma (hM): Analysis of a Southwest Oncology Group trial.

Vaishali Santhorawala

2 #8023-Weekly and twice-weekly bortezomib in AL amyloidosis: Results of a phase II study.

Donna Ellen Reece

3 #8024^ -Use of melphalan (M)/dexamethasone (D)/bortezomib in AL-amyloidosis.

Cristina Gasparetto

4 #8025-A phase II study of pomalidomide and dexamethasone in previously treated light-chain (AL) amyloidosis.

Angela Dispenzieri

5 #8026-Comparison of bortezomib- and lenalidomide-based therapies for the treatment of primary (AL) amyloidosis.

Daniel J. Landsburg

- Discussion: New developments in amyloidosis

Giampaolo Merlini, MD, PhD

6 #8027-Outcome with total therapy 3 (TT3) compared to total therapy 2 (TT2): Role of GEP70-defined high-risk disease with trisomy of 1q21 and activation of the proteasome gene *PSMD4*.

John D. Shaughnessy

7 #8028^ -Response of newly diagnosed myeloma with 1q21 amplification to bortezomib-based PAD induction therapy.

Douglas E Joshua

8 #8029-Dose-escalation study of carfilzomib (CFZ) plus lenalidomide (LEN) plus low-dose dexamethasone (Dex) (CRd) in relapsed/refractory multiple myeloma (R/R MM).

9 #8030^ -Phase I study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM).

Maria-Victoria Mateos

10 #8031-Phase I study of combined vorinostat (V), lenalidomide (L), and dexamethasone (D) in patients (pts) with relapsed or refractory multiple myeloma (MM).

Paul Gerard Guy Richardson, MD

11 #8032-Results of a phase I study of RAD001 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma.

Anuj Kumar Mahindra

- Discussion: Personalized therapy and new agents in myeloma

Robert Z. Orlowski, MD, PhD

12 #8033-Incorporation of rituximab and liposomal doxorubicin into CODOX-m/IVAC for HIV-negative and HIV-positive adult patients (pts) with untreated Burkitt's lymphoma (BL): Preliminary results of a multicenter phase II study.

Stephanie A. Gregory

13 #8034-A phase II trial of pegylated doxorubicin, rituximab, cyclophosphamide, vincristine and prednisone (DR-COP) in patients with newly diagnosed AIDS-associated B-cell non-Hodgkin's lymphoma (ARL): An AIDS Malignancy Consortium Trial (AMC 047).

Alexandra M. Levine

14 #8035-HIV-associated Hodgkin's lymphoma (HIV-HL): Results of a prospective multicenter trial.

Marcus Hentrich

- Discussion: Approaches for HIV associated lymphoma

Lawrence D. Kaplan, MD

15 #8036-Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma.

Nathan Hale Fowler

16 #8037-Lenalidomide (LEN) in patients with transformed lymphoma: Results from a large international phase II study (NHL-003).

Craig B. Reeder

17 #8038-Response of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with non-germinal center B-cell phenotype to lenalidomide (L) alone or in combination with rituximab (R).

Francisco J. Hernandez-Ilizaliturri

18 #8039-Galiximab, an anti-CD80 primatized monoclonal antibody, in relapsed Hodgkin lymphoma: Final results of CALGB 50602.

Sonali M. Smith

19 #8040-Enzastaurin in patients with follicular lymphoma: Results of a phase II study.

Lee Schwartzberg

20 #8041-Bendamustine/rituximab in relapsed or refractory diffuse large B-cell lymphoma.

Jeffrey L. Vacirca

21 #8042[^]-Ofatumumab combined with CHOP in previously untreated patients with follicular lymphoma (FL).

Myron Stefan Czuczman, MD

- Discussion: Novel agents in lymphoma

Nancy Bartlett, MD

22 #8043-Phase II trial of daclizumab in human T-cell lymphotropic virus type-1 (HTLV-1)-associated adult T-cell leukemia/lymphoma (ATL).

Jonathan Laurence Berkowitz, MD, PhD

23 #8044-Phase II study of SMILE chemotherapy for newly-diagnosed stage IV, relapsed or refractory extranodal NK/T-cell lymphoma, nasal type: NKTSG study.

Motoko Yamaguchi, MD, PhD

24 #8045-Phase II study of denileukin diftitox with CHOP chemotherapy in newly-diagnosed PTCL: CONCEPT trial.

Francine M. Foss, MD

25 #8046-A phase I/II trial of clofarabine in patients with relapsed T-cell or NK-cell lymphomas.

Deborah A. Mulford

Session Title: #13: Application of Epigenetics to Diagnosis and Therapy

Session Type: Education Session

Date: Friday, June 4

Location: S406 (Vista Room)

Time: 2:45 PM - 4:00 PM

- Cancer Epigenetics- Basic Biology

Gerd P Pfeifer, PhD

- Can we use epigenetics in early detection of cancer?

Paul Cairns, PhD

- Use of epigenetic information for individualized cancer care

Jean Pierre Issa, MD